The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press10210.17650/1818-8338-2011-3-55-60ORIGINAL INVESTIGATIONSОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕPREVENTION OF ANTRACYCLIN ANTIBIOTIC DOXORUBICIN СARDIOTOXICITY: A ROLE OF ACE-INHIBITOR PERINDOPRILПРОФИЛАКТИКА КАРДИОТОКСИЧЕСКОГО ДЕЙСТВИЯ АНТРАЦИКЛИНОВОГО АНТИБИОТИКА ДОКСОРУБИЦИНА: РОЛЬ ИНГИБИТОРА АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА ПЕРИНДОПРИЛАPravdivtsevaE. V.ПравдивцеваЕ. В.
Russian Federation
katiku@yandex.ruPoteshkinaN. G.ПотешкинаН. Г.
Russian Federation
SvanadzeA. M.СванадзеА. М.
Russian Federation
RilskiyD. S.РыльскийД. С.
Russian Federation
The Russian National Research Medical University named after N.I.PirogovГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздравсоцразвития России150720115355601707201417072014Copyright ©; 2011, Pravdivtseva E.V., Poteshkina N.G., Svanadze A.M., Rilskiy D.S.Copyright ©; 2011, Правдивцева Е.В., Потешкина Н.Г., Сванадзе А.М., Рыльский Д.С.2011Pravdivtseva E.V., Poteshkina N.G., Svanadze A.M., Rilskiy D.S.Правдивцева Е.В., Потешкина Н.Г., Сванадзе А.М., Рыльский Д.С.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/102

Aim – to study how anthracyclines influence on cardiovascular system in patients with lymphomas and whether angiotensin-converting enzyme inhibitor Perindopril is cardioprotective in these patients.

Subjects and methods. 26 patients with Hodgkin’s disease and non-Hodgkin’s lymphomas were followed before and after treatment withdoxorubicin. 12 of these patients with arterial hypertension received angiotensin-converting enzyme inhibitor Рerindopril, 10 mg/d, duringtreatment with doxorubicin. Cardiological evaluation was performed before and the next day after chemotherapy. Average dose of Doxorubicin was 34,99 ± 13,23 mg/m2.

Results. In patients receiving anthracyclines deceleration time DT increased significantly, a significant reduction in heart rate (HR), cardiacoutput (CO) and cardiac index (CI) were observed also (рDT = 0,037, pHR = 0,048, рСО = 0,007, рCI = 0,007). In patients simultaneouslytreated with Perindopril these parameters were not statistically different (рDT = 0,92, pHR = 0,22, рCO = 0,35, рCI = 0,39).

Conclusion. Administration of anthracyclines (average dose of Doxorubicin 34,99 ± 13,23 mg/m2) leads to DT of the left ventricle andreduction in HR, CJ and CI. Simultaneous treatment with Perindopril in patients receiving anthracyclines preserves DF and prevents heart hemodynamics abnormalities.

angiotensin-converting enzyme inhibitorantracyclin cardiotoxicitydiastolic disfunctionchemotherapyингибиторы ангиотензинпревращающего ферментаантрациклиновая кардиомиопатиядиастолическая дисфункцияхимиотерапия1. Российская Федерация: Федеральная служба государственной статистики. URL: http://www.gks.ruРоссийская Федерация: Федеральная служба государственной статистики. URL: http://www.gks.ru2. Всемирная организация здравоохранения. URL: http://www.who.int/features/qa/15/ru/index.htmlВсемирная организация здравоохранения. URL: http://www.who.int/features/qa/15/ru/index.html3. Химиотерапия опухолевых заболеваний. Краткое руководство. Под ред. Н.И. Переводчиковой. М., 2000.Химиотерапия опухолевых заболеваний. Краткое руководство. Под ред. Н.И. Переводчиковой. М., 2000.4. Ewer M.S., Benjamin R.S. Cardiotoxicity of chemotherapeutic drugs. In: The chemotherapy source book. M.C. Perry, ed. Lippincott Williams & Wilkins, 1997. P. 649–63.Ewer M.S., Benjamin R.S. Cardiotoxicity of chemotherapeutic drugs. In: The chemotherapy source book. M.C. Perry, ed. Lippincott Williams & Wilkins, 1997. P. 649–63.5. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001;19:37–43.Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001;19:37–43.6. Cardinale D., Colombo A., Sandri M. et al. Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–81.Cardinale D., Colombo A., Sandri M. et al. Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–81.7. Jensen B.V., Nielsen S.L., Skovsgaard T. Treatment with angiotensin-convertingenzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996;347:297–9.Jensen B.V., Nielsen S.L., Skovsgaard T. Treatment with angiotensin-convertingenzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996;347:297–9.8. Silber J.H., Cnaan A., Clark B.J. et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820–8.Silber J.H., Cnaan A., Clark B.J. et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820–8.9. Okumura K., Jin D., Takai S., Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 2002;88:183–8.Okumura K., Jin D., Takai S., Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 2002;88:183–8.10. Tokudome T., Mizushige K., Noma T. et al. Prevention of doxorubicin (adriamycin)- induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000;36:361–8.Tokudome T., Mizushige K., Noma T. et al. Prevention of doxorubicin (adriamycin)- induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000;36:361–8.11. Ершов В.И., Литвицкий П.Ф., Кочкарева Ю.Б. Свободнорадикальные перикисные процессы и кардиотоксичность при лечении злокачественных лимфом. Клиническая медицина 2006;(9):47–51.Ершов В.И., Литвицкий П.Ф., Кочкарева Ю.Б. Свободнорадикальные перикисные процессы и кардиотоксичность при лечении злокачественных лимфом. Клиническая медицина 2006;(9):47–51.12. Chopra M., Beswick H., Clapperton M., et al. Antioxidant effects of angiotensinconvertingChopra M., Beswick H., Clapperton M., et al. Antioxidant effects of angiotensinconvertingenzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydrylcontaining ACE inhibitors. J CardiovascPharmacol 1992;19:330–40.13. Шевченко Ю.Л., Бобров Л.Л., Обрезан А.Г. и др. Изменения диастолической функции левого желудочка сердца у больных лимфогранулематозом. Клиническая медицина 2001;(6):20–3.Шевченко Ю.Л., Бобров Л.Л., Обрезан А.Г. и др. Изменения диастолической функции левого желудочка сердца у больных лимфогранулематозом. Клиническая медицина 2001;(6):20–3.14. Ватутин Н.Т., Калинкина Н.В., Кетинг Е.В. и др. Изменения функционального состояния левого желудочка при воздействии антрациклиновых антибиотиков. Кардиология 2001;(6):46.Ватутин Н.Т., Калинкина Н.В., Кетинг Е.В. и др. Изменения функционального состояния левого желудочка при воздействии антрациклиновых антибиотиков. Кардиология 2001;(6):46.15. Шевченко Ю.Л., Бобров Л.Л., Новик А.А. и др. Изменение диастолической функции левого желудочка сердца у больных с неходжкинскими лимфомами. Кардиология 2001;(9):51–5.Шевченко Ю.Л., Бобров Л.Л., Новик А.А. и др. Изменение диастолической функции левого желудочка сердца у больных с неходжкинскими лимфомами. Кардиология 2001;(9):51–5.16. Fujita N., Hiroe M., Ohta Y. et al. Chronic effects of metoprolol on myocardial j3-adrenergic receptors in doxorubicin-induced cardiac damage in rats. J Cardiovasc Pharmacol 1991;17:656–61.Fujita N., Hiroe M., Ohta Y. et al. Chronic effects of metoprolol on myocardial j3-adrenergic receptors in doxorubicin-induced cardiac damage in rats. J Cardiovasc Pharmacol 1991;17:656–61.17. Robison T.W., Giri S.N. Effects of chronic administration of doxorubicin on myocardial j3-adrenergic receptors. Life Sci 1986;39:731–6.Robison T.W., Giri S.N. Effects of chronic administration of doxorubicin on myocardial j3-adrenergic receptors. Life Sci 1986;39:731–6.18. Tong J., Ganguly P.K., Singal P.K. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 1991;260(3 Pt 2):909–16.Tong J., Ganguly P.K., Singal P.K. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 1991;260(3 Pt 2):909–16.